Actinogen Medical Past Earnings Performance
Past criteria checks 0/6
Actinogen Medical's earnings have been declining at an average annual rate of -11.8%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 1.5% per year.
Key information
-11.8%
Earnings growth rate
6.2%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 1.5% |
| Return on equity | -124.1% |
| Net Margin | -310.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Apr 30
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Nov 16Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Aug 02We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth
Apr 12We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely
Nov 28Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Aug 09Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Apr 07We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn
Oct 24Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business
Jul 11We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow
Mar 27How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?
Jan 07
Revenue & Expenses BreakdownBeta
How Actinogen Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -15 | 7 | 12 |
| 30 Sep 23 | 5 | -13 | 7 | 11 |
| 30 Jun 23 | 5 | -11 | 7 | 9 |
| 31 Mar 23 | 5 | -11 | 6 | 9 |
| 31 Dec 22 | 5 | -11 | 6 | 10 |
| 30 Sep 22 | 4 | -10 | 5 | 9 |
| 30 Jun 22 | 4 | -9 | 5 | 8 |
| 31 Mar 22 | 3 | -8 | 4 | 7 |
| 31 Dec 21 | 2 | -7 | 4 | 5 |
| 30 Sep 21 | 2 | -6 | 3 | 4 |
| 30 Jun 21 | 2 | -4 | 3 | 2 |
| 31 Mar 21 | 2 | -4 | 3 | 3 |
| 31 Dec 20 | 3 | -4 | 3 | 3 |
| 30 Sep 20 | 3 | -4 | 3 | 4 |
| 30 Jun 20 | 4 | -5 | 3 | 6 |
| 31 Mar 20 | 5 | -6 | 3 | 7 |
| 31 Dec 19 | 6 | -7 | 4 | 8 |
| 30 Sep 19 | 5 | -8 | 4 | 9 |
| 30 Jun 19 | 5 | -10 | 3 | 11 |
| 31 Mar 19 | 4 | -10 | 2 | 11 |
| 31 Dec 18 | 3 | -10 | 2 | 11 |
| 30 Sep 18 | 3 | -8 | 2 | 9 |
| 30 Jun 18 | 3 | -6 | 1 | 8 |
| 31 Mar 18 | 2 | -6 | 1 | 6 |
| 31 Dec 17 | 2 | -5 | 1 | 5 |
| 30 Sep 17 | 1 | -4 | 1 | 4 |
| 30 Jun 17 | 1 | -3 | 1 | 3 |
| 31 Mar 17 | 2 | -4 | 1 | 4 |
| 31 Dec 16 | 3 | -4 | 1 | 5 |
| 30 Sep 16 | 3 | -4 | 1 | 5 |
| 30 Jun 16 | 4 | -4 | 2 | 6 |
| 31 Mar 16 | 3 | -5 | 2 | 5 |
| 31 Dec 15 | 1 | -5 | 3 | 4 |
| 30 Sep 15 | 1 | -5 | 3 | 3 |
| 30 Jun 15 | 0 | -5 | 3 | 3 |
| 31 Mar 15 | 0 | -3 | 2 | 2 |
| 31 Dec 14 | 0 | -2 | 1 | 1 |
| 30 Sep 14 | 0 | -1 | 1 | 0 |
| 30 Jun 14 | 0 | 0 | 0 | 0 |
| 31 Mar 14 | 0 | 0 | 0 | 0 |
| 31 Dec 13 | 0 | 0 | 0 | 0 |
| 30 Sep 13 | 0 | 0 | 0 | 0 |
| 30 Jun 13 | 0 | 0 | 0 | 0 |
Quality Earnings: ACW is currently unprofitable.
Growing Profit Margin: ACW is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACW is unprofitable, and losses have increased over the past 5 years at a rate of 11.8% per year.
Accelerating Growth: Unable to compare ACW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).
Return on Equity
High ROE: ACW has a negative Return on Equity (-124.14%), as it is currently unprofitable.